Last edition
News about "HEALING clinical trial"
Aplagon Doses First Patient in Phase IIa Trial of APAC for Chronic Limb-Threatening Ischemia
Aplagon has dosed the first patient in its Phase IIa HEALING trial evaluating APAC therapy for Chronic Limb?Threatening Ischemia caused by Peripheral Arterial Occlusive Disease in Finland.
HEALING Clinical Trial | 16/03/2026 | By News Bureau | 113
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members